72 citations
,
January 2011 in “Current Pharmaceutical Design” This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.
223 citations
,
December 2010 in “The Journal of Sexual Medicine” This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.
1 citations
,
August 2015 in “Current Sexual Health Reports” This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.
18 citations
,
March 2020 in “Frontiers in Neuroendocrinology” This study suggests that synthetic steroid analogues or 5α-reductase modulation could be potential therapeutic strategies for nervous system disorders, but further research on their effects is necessary.
248 citations
,
December 2011 in “Journal of Neuroscience” This study demonstrated that stress-derived neurosteroid THDOC shifts from inhibiting to activating the HPA axis under stress, presenting potential therapeutic targets for stress-related disorders.